N. Aaronson, S. Ahmedzai, B. Bergman, M. Bullinger, A. Cull et al., The European-OrganizationFor-Research-And-Treatment-Of-Cancer QLQ-C30 -A Quality-Of-Life Instrument for Use in International Clinical-Trials in Oncology, J. Natl. Cancer Inst, vol.85, pp.365-76, 1993.

C. Abrial, F. Bouchet-mishellany, I. Raoelfils, A. Cayre, H. Curé et al., Place de l'anatomopathologie dans l'évaluation de la réponse à la chimiothérapie néoadjuvante : marqueurs pronostiques et prédictifs. L'exemple du cancer du sein, Bull. Cancer (Paris), vol.93, issue.7, pp.663-668, 2006.

F. Ades, D. Zardavas, A. C. Pinto, C. Criscitiello, P. Aftimos et al., Cardiotoxicity of systemic agents used in breast cancer, Breast Edinb. Scotl, vol.23, issue.4, pp.317-328, 2014.

K. J. Ahn, J. Park, and Y. Choi, Lymphovascular invasion as a negative prognostic factor for triple-negative breast cancer after surgery, Radiat. Oncol. J, vol.35, issue.4, pp.332-339, 2017.

A. , Agence Nationale d'Accréditation et d'Evaluation en Santé (ANAES), Acta Endosc, vol.28, issue.2, pp.151-155, 1998.

A. , ANAES, 2002.

C. Anders, P. K. Marcom, B. Peterson, L. Gu, S. Unruhe et al., A Pilot Study of Predictive Markers of Chemotherapy-Related Amenorrhea Among Premenopausal Women with Early Stage Breast Cancer, Cancer Invest, vol.26, issue.3, pp.286-295, 2008.

A. Carey and L. A. , Understanding and Treating Triple-Negative Breast Cancer, Oncol. Williston Park N, vol.22, issue.11, pp.1233-1243, 2008.

C. K. Anders, R. Johnson, J. Litton, M. Phillips, and A. Bleyer, Breast Cancer Before Age 40 Years, Semin. Oncol, vol.36, issue.3, pp.237-249, 2009.

G. L. Anderson, M. Limacher, A. R. Assaf, T. Bassford, S. A. Beresford et al., Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial, JAMA, vol.291, issue.14, pp.1701-1712, 2004.

R. A. Anderson, J. Mansi, R. E. Coleman, D. J. Adamson, and R. C. Leonard, The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer, Eur. J. Cancer, vol.87, pp.58-64, 2017.

A. Antoniou, P. D. Pharoah, S. Narod, H. A. Risch, J. E. Eyfjord et al., Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies, Am. J. Hum. Genet, vol.72, issue.5, pp.1117-1130, 2003.

. Asco, ASCO Guideline Update Recommends Tamoxifen for Up to 10 Years for Women With Non-Metastatic Hormone Receptor Positive Breast Cancer, 2014.

, Surgical guidelines for the management of breast cancer, Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol, vol.35, pp.1-22, 2009.

N. E. Avis, S. F. Assmann, H. M. Kravitz, P. A. Ganz, and M. Ory, Quality of Life in Diverse Groups of Midlife Women: Assessing the Influence of Menopause, Health Status and Psychosocial and Demographic Factors, Qual. Life Res, vol.13, issue.5, pp.933-946, 2004.

S. Azam, T. Lange, S. Huynh, A. R. Aro, M. Euler-chelpin et al., Hormone replacement therapy, mammographic density, and breast cancer risk: a cohort study, Cancer Causes Control CCC, vol.29, issue.6, pp.495-505, 2018.

M. S. Bae, H. Moon, W. Han, D. Noh, H. S. Ryu et al., Early Stage Triple-Negative Breast Cancer: Imaging and Clinical-Pathologic Factors Associated with Recurrence, Radiology, vol.278, issue.2, pp.356-364, 2016.

T. G. Baker and Z. Solly, A quantitative and cytological study of germ cells in human ovaries, Proc. R. Soc. Lond. B Biol. Sci, vol.158, issue.972, pp.417-433, 1963.

A. J. Balaton, V. L. Doussal, L. Arnould, C. Barlier, J. P. Bellocq et al., Recommandations pour l'évaluation immunohistochimique des récepteurs hormonaux sur coupes en paraffine dans les carcinomes mammaires Mise à jour 1999, 1999.

C. Balleyguier and I. Thomassin-naggara, BI-RADS 2013 en mammographie : petit guide des nouveautés, Imag. Femme, vol.25, issue.1, pp.1-7, 2015.

R. L. Barbieri, P. M. Rosenwaks, and . Wassarman, The Endocrinology of the Menstrual Cycle, Human Fertility: Methods and Protocols, pp.145-169, 2014.

K. R. Bauer, M. Brown, R. D. Cress, C. A. Parise, and V. Caggiano, Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry, Cancer, vol.109, issue.9, pp.1721-1728, 2007.

V. Beral, Breast cancer and hormonereplacement therapy in the Million Women Study, Lancet Lond. Engl, vol.362, issue.9382, pp.419-427, 2003.

L. Bernstein, Epidemiology of Endocrine-Related Risk Factors for Breast Cancer, J. Mammary Gland Biol. Neoplasia, vol.7, issue.1, pp.3-15, 2002.

A. Bertaut, M. Mounier, I. Desmoulins, F. Beltjens, L. Arnould et al., Impact pronostique du statut des récepteurs hormonaux et HER2 sur la survie des femmes atteintes d'un cancer du sein de stade IV : étude à partir du registre spécialisé de Côte-d, Or. Rev. DÉpidémiologie Santé Publique, vol.62, pp.213-214, 2014.

F. Binder-foucard, A. Belot, P. Delafosse, L. Remontet, A. Woronoff et al., Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2012 -Partie 1 -Tumeurs solides -Ref : RAPTUMSOL13 | Institut National Du Cancer, 2013.

J. Bines, D. M. Oleske, and M. A. Cobleigh, Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer, J. Clin. Oncol, vol.14, issue.5, pp.1718-1729, 1996.

A. Bleyer, M. O'leary, R. Barr, and L. Ries, Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival, pp.6-5767, 1975.

J. M. Bliss, L. S. Kilburn, R. E. Coleman, J. F. Forbes, A. S. Coates et al., Diseaserelated outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.30, issue.7, pp.709-717, 2012.

E. Block, Quantitative morphological investigations of the follicular system in women; variations at different ages, Acta Anat. (Basel), vol.14, issue.1-2, pp.108-123, 1952.

J. R. Bloom, S. L. Stewart, M. Johnston, and P. Banks, Intrusiveness of illness and quality of life in young women with breast cancer, Psychooncology, vol.7, issue.2, pp.89-100, 1998.

T. Bouillet, X. Bigard, C. Brami, K. Chouahnia, L. Copel et al., Role of physical activity and sport in oncology: scientific commission of the National Federation Sport and Cancer CAMI, Crit. Rev. Oncol. Hematol, vol.94, issue.1, pp.74-86, 2015.

M. J. Brady, D. F. Cella, F. Mo, A. E. Bonomi, D. S. Tulsky et al., Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.15, issue.3, pp.974-986, 1997.

C. Braga, E. Negri, C. La-vecchia, R. Filiberti, and S. Franceschi, Cigarette smoking and the risk of breast cancer, Eur. J. Cancer Prev. Off. J. Eur. Cancer Prev. Organ. ECP, vol.5, issue.3, pp.159-164, 1996.

H. R. Brewer, M. E. Jones, M. J. Schoemaker, A. Ashworth, and A. J. Swerdlow, Family history and risk of breast cancer: an analysis accounting for family structure, Breast Cancer Res. Treat, vol.165, issue.1, pp.193-200, 2017.

L. A. Brinton, C. Schairer, R. N. Hoover, and J. F. Fraumeni, Menstrual factors and risk of breast cancer, Cancer Invest, vol.6, issue.3, pp.245-254, 1988.

M. Broeders, S. Moss, L. Nyström, S. Njor, H. Jonsson et al., The Impact of Mammographic Screening on Breast Cancer Mortality in Europe: A Review of Observational Studies, J. Med. Screen, vol.19, pp.14-25, 2012.

F. J. Broekmans, M. R. Soules, and B. C. Fauser, Ovarian Aging: Mechanisms and Clinical Consequences, Endocr. Rev, vol.30, issue.5, pp.465-493, 2009.

W. D. Den-brok, C. H. Speers, L. Gondara, E. Baxter, S. K. Tyldesley et al., Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed, Breast Cancer Res. Treat, vol.161, issue.3, pp.549-556, 2017.

H. G. Burger, Unpredictable endocrinology of the menopause transition: clinical, diagnostic and management implications, Menopause Int, vol.17, issue.4, pp.153-154, 2011.

H. J. Burstein, S. Temin, H. Anderson, T. A. Buchholz, N. E. Davidson et al., Adjuvant endocrine therapy for women with hormone receptorpositive breast cancer: american society of clinical oncology clinical practice guideline focused update, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.32, issue.21, pp.2255-2269, 2014.

M. D. Burstein, A. Tsimelzon, G. M. Poage, K. R. Covington, A. Contreras et al., Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.21, issue.7, pp.1688-1698, 2015.

, Cancer du sein chez l'homme -Cancer du sein | Institut National Du Cancer, 2018.

, Comprehensive molecular portraits of human breast tumours, Nature, vol.490, issue.7418, pp.61-70, 2012.

L. A. Carey, E. C. Dees, L. Sawyer, L. Gatti, D. T. Moore et al., The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes, Clin. Cancer Res, vol.13, issue.8, pp.2329-2334, 2007.

C. Catsburg, R. S. Kim, V. A. Kirsh, C. L. Soskolne, N. Kreiger et al., Dietary patterns and breast cancer risk: a study in 2 cohorts, Am. J. Clin. Nutr, vol.101, issue.4, pp.817-823, 2015.

C. Cedolini, S. Bertozzi, A. P. Londero, S. Bernardi, L. Seriau et al., Type of breast cancer diagnosis, screening, and survival, Clin. Breast Cancer, vol.14, issue.4, pp.235-240, 2014.

D. F. Cella, D. S. Tulsky, G. Gray, B. Sarafian, E. Linn et al., The Functional Assessment of Cancer Therapy scale: development and validation of the general measure, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.11, issue.3, pp.570-579, 1993.

, National Center for Chronic Disease Prevention and Health Promotion (US), and Office on Smoking and Health (US), Centers for Disease Control and Prevention (US)

, How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General, 2018.

. Cghfbc, Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies, The Lancet, vol.347, issue.9017, pp.1713-1727, 1996.

V. E. Chen, E. F. Gillespie, K. Zakeri, J. D. Murphy, C. M. Yashar et al., Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer, Adv. Radiat. Oncol, vol.2, issue.2, pp.105-109, 2017.

W. Chen, A. D. Hoffmann, H. Liu, and X. Liu, Organotropism: new insights into molecular mechanisms of breast cancer metastasis, NPJ Precis. Oncol, vol.2, issue.1, 2018.

G. Chene, , 2019.

, Gynecol. Obstet. Fertil. Senol, vol.47, issue.2, pp.91-92

G. Chene, B. De-rochambeau, L. Bail-carval, K. Beaufils, E. Chabert et al., , 2016.

, Gynécologie Obstétrique Fertil, vol.44, issue.7, pp.377-384

B. Chevallier, H. Roche, J. P. Olivier, P. Chollet, and P. Hurteloup, Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate, Am. J. Clin. Oncol, vol.16, issue.3, pp.223-228, 1993.

R. T. Chlebowski, S. L. Hendrix, R. D. Langer, M. L. Stefanick, M. Gass et al., Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial, JAMA, vol.289, issue.24, pp.3243-3253, 2003.

P. Chollet, C. Abrial, X. Durando, E. Thivat, O. Tacca et al., A new prognostic classification after primary chemotherapy for breast cancer: residual disease in breast and nodes (RDBN), Cancer J. Sudbury Mass, vol.14, issue.2, pp.128-132, 2008.

P. Chollet, H. Curé, S. Amat, A. Mouret-reynier, M. Penault-llorca et al., Chimiothérapie néo-adjuvante. Expérience du centre Jean-Perrin. Importance de la tumeur résiduelle et de la rémission histologique complète, pp.293-306, 2006.

V. Christophe, C. Duprez, A. Congard, E. Fournier, A. Lesur et al., Evaluate the subjective experience of the disease and its treatment in the partners of young women with non-metastatic breast cancer, Eur. J. Cancer Care (Engl.), vol.25, issue.5, pp.734-743, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01470061

D. Cibula, A. Gompel, A. O. Mueck, L. Vecchia, C. Hannaford et al., Hormonal contraception and risk of cancer, Hum. Reprod. Update, vol.16, issue.6, pp.631-650, 2010.

G. M. Clark and W. L. Mcguire, Steroid receptors and other prognostic factors in primary breast cancer, Semin. Oncol, vol.15, issue.2, pp.20-25, 1988.

R. B. Clarke, Steroid receptors and proliferation in the human breast, Steroids, vol.68, pp.789-794, 2003.

M. Clemons and P. Goss, Estrogen and the risk of breast cancer, N. Engl. J. Med, vol.344, issue.4, pp.276-285, 2001.

A. S. Coates, E. P. Winer, A. Goldhirsch, R. D. Gelber, M. Gnant et al., Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, vol.26, pp.1533-1546, 2015.

G. A. Colditz, W. C. Willett, D. J. Hunter, M. J. Stampfer, J. E. Manson et al., Family History, Age, and Risk of Breast Cancer: Prospective Data From the Nurses' Health Study, JAMA, vol.270, issue.3, pp.338-343, 1993.

, Collège National des Gynécologues et Obstétriciens Français, J. Gynécologie Obstétrique Biol. Reprod, vol.34, issue.5, p.513, 2005.

S. A. Cooper, On the anatomy of the breast -Of the internal parts of the breast, or mammary gland. Anat. Breast Sir Astley Paston Cooper 1840, 1840.

P. Cortazar, L. Zhang, M. Untch, K. Mehta, J. P. Costantino et al., Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis, Lancet Lond. Engl, vol.384, issue.9938, pp.62422-62430, 2014.

J. Cortés, F. André, A. Gonçalves, S. Kümmel, M. Martín et al., IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer, Future Oncol. Lond. Engl, 2019.

F. J. Couch, H. Shimelis, C. Hu, S. N. Hart, E. C. Polley et al., Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer, JAMA Oncol, vol.3, issue.9, pp.1190-1196, 2017.

H. Curé, S. Amat, F. Penault-llorca, G. Le-bouëdec, J. Ferrière et al., Prognostic value of residual node involvement in operable breast cancer after induction chemotherapy, Breast Cancer Res. Treat, vol.76, issue.1, pp.37-45, 2002.

J. Cuzick, I. Sestak, M. Baum, A. Buzdar, A. Howell et al., Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial, Lancet Oncol, vol.11, issue.12, pp.70257-70263, 2010.

A. Dandamudi, J. Tommie, L. Nommsen-rivers, and S. Couch, Dietary Patterns and Breast Cancer Risk: A Systematic Review, Anticancer Res, vol.38, issue.6, pp.3209-3222, 2018.

C. Davies, H. Pan, J. Godwin, R. Gray, R. Arriagada et al., Longer Against Shorter (ATLAS) Collaborative Group. 2013. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial, vol.381, pp.61963-61964

S. R. Davis, I. Lambrinoudaki, M. Lumsden, G. D. Mishra, L. Pal et al., Menopause. Nat. Rev. Dis. Primer, vol.1, p.15004, 2015.

S. Dawood, K. Broglio, F. J. Esteva, W. Yang, S. Kau et al., Survival among women with triple receptor-negative breast cancer and brain metastases, Ann. Oncol, vol.20, issue.4, pp.621-627, 2009.

T. Delozier, J. P. Julien, P. Juret, C. Veyret, J. E. Couëtte et al., Adjuvant tamoxifen in postmenopausal breast cancer: preliminary results of a randomized trial, Breast Cancer Res. Treat, vol.7, issue.2, pp.105-109, 1986.

L. Dennerstein, E. C. Dudley, J. L. Hopper, J. R. Guthrie, and H. G. Burger, A prospective population-based study of menopausal symptoms, Obstet. Gynecol, vol.96, issue.3, pp.351-358, 2000.

R. Dent, W. M. Hanna, M. Trudeau, E. Rawlinson, P. Sun et al., Pattern of metastatic spread in triple-negative breast cancer, Breast Cancer Res. Treat, vol.115, issue.2, pp.423-428, 2009.

A. Dezellus, P. Barriere, M. Campone, C. Lemanski, L. Vanlemmens et al., Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer, Eur. J. Cancer, vol.79, pp.72-80, 2017.

M. V. Dieci, C. Criscitiello, A. Goubar, G. Viale, P. Conte et al., Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol, vol.25, issue.3, pp.611-618, 2014.

M. V. Dieci, N. Radosevic-robin, S. Fineberg, G. Van-den-eynden, N. Ternes et al., Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno, Oncology Biomarker Working Group on Breast Cancer. Semin. Cancer Biol, vol.52, pp.16-25, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01675219

J. Dohou, M. Mouret-reynier, F. Kwiatkowski, M. Arbre, P. Herviou et al., A Retrospective Study on the Onset of Menopause after Chemotherapy: Analysis of Data Extracted from the Jean Perrin Comprehensive Cancer Center Database Concerning 345 Young Breast Cancer Patients Diagnosed between, Oncology, vol.92, issue.5, pp.255-263, 1994.
URL : https://hal.archives-ouvertes.fr/hal-01675233

C. D'orsi, E. Mendelson, and . Morris, ACR BI-RADS® Atlas 5th Edition ebook, 2013.

L. Dossus, M. Boutron-ruault, R. Kaaks, I. T. Gram, A. Vilier et al., Active and passive cigarette smoking and breast cancer risk: Results from the EPIC cohort, Int. J. Cancer, vol.134, issue.8, pp.1871-1888, 2014.

M. Dowsett, J. Cuzick, J. Ingle, A. Coates, J. Forbes et al., Metaanalysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.28, issue.3, pp.509-518, 2010.

M. Dowsett, T. O. Nielsen, R. A'hern, J. Bartlett, R. C. Coombes et al., Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group, JNCI J. Natl. Cancer Inst, vol.103, issue.22, pp.1656-1664, 2011.

, Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women, N. Engl. J. Med, vol.319, issue.26, pp.1681-1692, 1988.

, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet Lond. Engl, vol.365, issue.9472, pp.1687-1717, 2005.

, Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials, Lancet, vol.378, issue.9793, pp.60993-61001, 2011.

S. Darby, P. Mcgale, C. Correa, C. Taylor, R. Arriagada et al., Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials, Lancet Lond. Engl, vol.378, issue.9804, pp.61629-61631, 2011.

P. Mcgale, C. Taylor, C. Correa, D. Cutter, F. Duane et al., Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: metaanalysis of individual patient data for 8135 women in 22 randomised trials, Lancet Lond. Engl, vol.383, issue.9935, pp.60488-60496, 2014.

*. Eisinger, F. Bressac, B. Castaigne, D. Cottu, P. Lansac et al., Réponse du Groupe technique national sur le dépistage du cancer du sein, Bull. Cancer (Paris), vol.91, issue.7, pp.656-656, 2004.

I. O. Ellis, M. Galea, N. Broughton, A. Locker, R. W. Blamey et al., Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up, Histopathology, vol.20, issue.6, pp.479-489, 1992.

C. W. Elston and I. O. Ellis, Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with longterm follow-up, Histopathology, vol.19, issue.5, pp.403-410, 1991.

, Available from https://ecis.jrc.ec.europa.eu/explorer.php?$1-IT$2-127$4-2$3-29$6-0,85$5-2004, 2012.

, Fact Sheets by Cancer, p.10, 2018.

M. J. Faddy, R. G. Gosden, A. Gougeon, S. J. Richardson, and J. F. Nelson, Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause, Hum. Reprod. Oxf. Engl, vol.7, issue.10, pp.1342-1346, 1992.

S. S. Faubion, C. L. Kuhle, L. T. Shuster, and W. A. Rocca, Long-term health consequences of premature or early menopause and considerations for management, Climacteric J. Int. Menopause Soc, vol.18, issue.4, pp.483-491, 2015.

A. Fauci, E. Braunwald, D. L. Kasper, S. L. Hauser, D. Longo et al., Harrison's Principles of Internal Medicine, 2008.

. Fda, Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance, Health Qual. Life Outcomes, vol.4, p.79, 2006.

F. Fei, C. Messina, L. Slaets, C. Chakiba, D. Cameron et al., Tumour size is the only predictive factor of distant recurrence after pathological complete response to neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancers: A sub-study of EORTC 10994/BIG 1-00 phase III trial, Eur. J. Cancer, vol.51, issue.3, pp.301-309, 2015.

D. Felce, P. , and J. , Quality of life: its definition and measurement, Res. Dev. Disabil, vol.16, issue.1, pp.51-74, 1995.

. Feng, . Spezia, . Huang, . Yuan, . Zeng et al., Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis -ScienceDirect, p.29, 2018.

J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers et al., Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, Int. J. Cancer, vol.136, issue.5, pp.359-386, 2014.

J. Ferlay, E. Steliarova-foucher, J. Lortet-tieulent, S. Rosso, J. W. Coebergh et al., Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012, Eur. J. Cancer, vol.49, issue.6, pp.1374-1403, 2013.

W. Finck, J. Passildas, C. Poirier, F. Kwiatkowski, C. Abrial et al., Abstract P5-12-09: The ?5% cut-off reveals tumor PD-L1 positivity as potential selection biomarker for patient enrollment into the trials evaluating anti-PD-1 or anti-PD-L1 agents in neoadjuvant treatment of triple negative breast cancer, Cancer Res, vol.79, 2004.

S. W. Fletcher, W. Black, R. Harris, B. K. Rimer, and S. Shapiro, Report of the International Workshop on Screening for Breast Cancer, J. Natl. Cancer Inst, vol.85, issue.20, pp.1644-1656, 1993.

A. Fondation, Cancers du sein : le diagnostic | Fondation ARC pour la recherche sur le cancer. Available from /cancer/cancer-sein/diagnostic-cancer, 2018.

M. N. Fornier, S. Modi, K. S. Panageas, L. Norton, and C. Hudis, Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane, Cancer, vol.104, issue.8, pp.1575-1579, 2005.

A. Fournier, F. Berrino, E. Riboli, V. Avenel, and F. Clavel-chapelon, Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort, Int. J. Cancer, vol.114, issue.3, pp.448-454, 2005.
URL : https://hal.archives-ouvertes.fr/inserm-00129104

A. Fournier, F. Berrino, E. Riboli, V. Avenel, and F. Clavel-chapelon, Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort, Int. J. Cancer, vol.114, issue.3, pp.448-454
URL : https://hal.archives-ouvertes.fr/inserm-00129104

E. W. Freeman, M. D. Sammel, C. R. Gracia, S. Kapoor, H. Lin et al., Follicular phase hormone levels and menstrual bleeding status in the approach to menopause, Fertil. Steril, vol.83, issue.2, pp.383-392, 2005.

C. M. Friedenreich and A. E. Cust, Physical activity and breast cancer risk: impact of timing, type and dose of activity and population subgroup effects, Br. J. Sports Med, vol.42, issue.8, pp.636-647, 2008.

C. Gajdos, P. I. Tartter, I. J. Bleiweiss, C. Bodian, and S. T. Brower, Stage 0 to stage III breast cancer in young women11No competing interests declared, J. Am. Coll. Surg, vol.190, issue.5, pp.523-529, 2000.

T. Gamucci, A. Vaccaro, F. Ciancola, L. Pizzuti, I. Sperduti et al., Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis, J. Cancer Res. Clin. Oncol, vol.139, issue.5, pp.853-860, 2013.

P. A. Ganz, G. A. Greendale, L. Petersen, B. Kahn, and J. E. Bower, Breast Cancer in Younger Women: Reproductive and Late Health Effects of Treatment, J. Clin. Oncol, vol.21, issue.22, pp.4184-4193, 2003.

J. Gerdes, H. Lemke, H. Baisch, H. H. Wacker, U. Schwab et al., Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67, J. Immunol. Baltim. Md, vol.133, issue.4, pp.1710-1715, 1950.

F. C. Geyer, F. Pareja, B. Weigelt, E. Rakha, I. O. Ellis et al., The Spectrum of Triple-Negative Breast Disease: High-and Low-Grade Lesions, Am. J. Pathol, vol.187, issue.10, pp.2139-2151, 2017.

A. Ginzac, É. Thivat, M. Mouret-reynier, P. Dubray-longeras, I. Van-praagh et al., Weight Evolution During Endocrine Therapy for Breast Cancer in Postmenopausal Patients: Effect of Initial Fat Mass Percentage and Previous Adjuvant Treatments, Clin. Breast Cancer, vol.18, issue.5, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01834391

A. E. Giuliano, J. L. Connolly, S. B. Edge, E. A. Mittendorf, H. S. Rugo et al., Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA, Cancer J. Clin, vol.67, issue.4, pp.290-303, 2017.

A. E. Giuliano, K. K. Hunt, K. V. Ballman, P. D. Beitsch, P. W. Whitworth et al., Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial, JAMA, vol.305, issue.6, pp.569-575, 2011.

. Globocan, GLOBOCAN 2012 age-specific table, p.10, 2012.

, GLOBOCAN 2012 age-specific table. (n.d.). Available from, p.17, 2017.

M. Gnant, N. Harbeck, and C. Thomssen, Summary of the Consensus Discussion, Breast Care, vol.6, issue.2, pp.136-141, 2011.

E. Gobbini, M. Ezzalfani, V. Dieras, T. Bachelot, E. Brain et al., Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort, Eur. J. Cancer, vol.96, pp.17-24, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01930014

E. B. Gold, S. L. Crawford, N. E. Avis, C. J. Crandall, K. A. Matthews et al., Factors Related to Age at Natural Menopause: Longitudinal Analyses From SWAN, Am. J. Epidemiol, vol.178, issue.1, pp.70-83, 2013.

A. Goldhirsch, R. D. Gelber, M. J. Piccart-gebhart, E. De-azambuja, M. Procter et al., HERA) Trial Study Team. 2013a. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial, Lancet Lond. Engl, vol.382, issue.9897, pp.61094-61100

A. Goldhirsch, J. H. Glick, R. D. Gelber, A. S. Coates, B. Thürlimann et al., and Panel members. 2005. Meeting highlights: international expert consensus on the primary therapy of early breast cancer, vol.16, pp.1569-1583, 2005.

A. Goldhirsch, E. P. Winer, A. S. Coates, R. D. Gelber, M. Piccart-gebhart et al., Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, vol.24, pp.2206-2223, 2013.

H. Goldvaser, T. A. Barnes, B. ?eruga, D. W. Cescon, A. Ocaña et al., Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis, J. Natl. Cancer Inst, vol.110, issue.1, 2018.

A. Goodman, Premature Menopause in Young Breast Cancer Survivors: Effects on Quality of Life Not Well Studied, Oncol. Times, vol.26, issue.14, p.35, 2004.

P. J. Goodwin, M. Ennis, K. I. Pritchard, M. Trudeau, and N. Hood, Risk of menopause during the first year after breast cancer diagnosis, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.17, issue.8, pp.2365-2370, 1999.

P. E. Goss, J. N. Ingle, J. L. Pater, S. Martino, N. J. Robert et al., Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.26, issue.12, pp.1948-1955, 2008.

C. R. Gracia, M. D. Sammel, E. Freeman, M. Prewitt, C. Carlson et al., Impact of cancer therapies on ovarian reserve, Fertil. Steril, vol.97, issue.1, pp.134-140, 2012.

V. Graziano, A. Grassadonia, L. Iezzi, P. Vici, L. Pizzuti et al., Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients, Breast Edinb. Scotl, vol.44, pp.33-38, 2019.

S. Guiu, M. A. Mouret-reynier, M. Toure, and B. Coudert, Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy, J. Oncol, 2013.

F. J. Gujam, J. J. Going, J. Edwards, Z. M. Mohammed, and D. C. Mcmillan, The role of lymphatic and blood vessel invasion in predicting survival and methods of detection in patients with primary operable breast cancer, Crit. Rev. Oncol. Hematol, vol.89, issue.2, pp.231-241, 2014.

E. Hall, B. N. Frey, and C. N. Soares, Non-hormonal treatment strategies for vasomotor symptoms: a critical review, Drugs, vol.71, issue.3, pp.287-304, 2011.

N. Hamajima, K. Hirose, K. Tajima, T. Rohan, E. E. Calle et al., Br. J. Cancer, vol.87, issue.11, pp.1234-1245

T. Hamaoka, J. E. Madewell, D. A. Podoloff, G. N. Hortobagyi, and N. T. Ueno, Bone Imaging in Metastatic Breast Cancer. J. Clin. Oncol, vol.22, issue.14, pp.2942-2953, 2004.

M. E. Hammond, D. F. Hayes, M. Dowsett, D. C. Allred, K. L. Hagerty et al., of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer, J. Clin. Oncol, vol.28, issue.16, pp.2784-2795, 2010.

D. Hanahan and R. A. Weinberg, The hallmarks of cancer, Cell, vol.100, issue.1, pp.57-70, 2000.

D. Hanahan and R. A. Weinberg, Hallmarks of Cancer: The Next Generation, Cell, vol.144, issue.5, pp.646-674, 2011.

S. E. Hankinson, G. A. Colditz, J. E. Manson, W. C. Willett, D. J. Hunter et al., A prospective study of oral contraceptive use and risk of breast cancer (Nurses' Health Study, United States), Cancer Causes Control, vol.8, issue.1, pp.65-72, 1997.

D. Harari, Y. , and Y. , Molecular mechanisms underlying ErbB2/HER2 action in breast cancer, Oncogene, vol.19, issue.53, pp.6102-6114, 2000.

S. D. Harlow, M. Gass, J. E. Hall, R. Lobo, P. Maki et al., Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging, Fertil. Steril, vol.97, issue.4, pp.843-851, 2012.

. Has, Haute Autorité de Santé -Cancer du sein : modalités spécifiques de dépistage pour les femmes à haut risque, 2016.

M. A. Healey, K. A. Hirko, A. H. Beck, L. C. Collins, S. J. Schnitt et al., Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses' Health Study, Breast Cancer Res. Treat, vol.166, issue.2, pp.613-622, 2017.

J. Heinig, R. Witteler, R. Schmitz, L. Kiesel, and J. Steinhard, Accuracy of classification of breast ultrasound findings based on criteria used for BI-RADS, 2008.

, Ultrasound Obstet. Gynecol. Off. J. Int. Soc. Ultrasound Obstet. Gynecol, vol.32, issue.4, pp.573-578

J. A. Henderson, F. , and T. , Breast, Examination. In StatPearls. StatPearls Publishing, issue.2, 2018.

C. Hennequin, I. Barillot, D. Azria, Y. Belkacémi, M. Bollet et al., , 2016.

, Cancer Radiother. J. Soc. Francaise Radiother. Oncol, vol.20, pp.139-146

M. Hickey, R. A. Szabo, and M. S. Hunter, Non-hormonal treatments for menopausal symptoms, BMJ, vol.359, p.5101, 2017.

P. Hopwood, I. Fletcher, A. Lee, A. Ghazal, and S. , A body image scale for use with cancer patients, Eur. J. Cancer, vol.37, issue.2, pp.189-197, 2001.

J. Howard-anderson, P. A. Ganz, J. E. Bower, and A. L. Stanton, Quality of Life, Fertility Concerns, and Behavioral Health Outcomes in Younger Breast Cancer Survivors: A Systematic Review, JNCI J. Natl. Cancer Inst, vol.104, issue.5, pp.386-405, 2012.

G. R. Howe, T. Hirohata, T. G. Hislop, J. M. Iscovich, J. M. Yuan et al., Dietary factors and risk of breast cancer: combined analysis of 12 case-control studies, J. Natl. Cancer Inst, vol.82, issue.7, pp.561-569, 1990.

C. C. Hsieh, D. Trichopoulos, K. Katsouyanni, Y. , and S. , Age at menarche, age at menopause, height and obesity as risk factors for breast cancer: associations and interactions in an international case-control study, Int. J. Cancer, vol.46, issue.5, pp.796-800, 1990.

K. Hwang, J. Kim, J. Jung, J. H. Chang, Y. J. Chai et al., Impact of Breast Cancer Subtypes on Prognosis of Women with Operable Invasive Breast Cancer: A Population-based Study Using SEER Database, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, 2018.

, Alcohol Consumption and Ethyl Carbamate. International Agency for Research on Cancer, 2010.

, Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy, IARC Monogr. Eval. Carcinog. Risks Hum, vol.91, pp.1-528, 2007.

. Inca, Antécédents familiaux -Facteurs de risque | Institut National Du Cancer, 2016.

. Inca, INCA -Les cancers en France, 2018.

, Anatomie du sein -Cancer du sein, 2019.

M. Ibcsg),-castiglione-gertsch, A. O'neill, K. N. Price, A. Goldhirsch, A. S. Coates et al., Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial, International Breast Cancer Study Group, vol.95, issue.24, pp.1833-1846, 2003.

. Invs, Evaluation du programme de dépistage du cancer du sein / Evaluation des programmes de dépistage des cancers / Cancers / Maladies chroniques et traumatismes / Dossiers thématiques / Accueil, 2011.

K. Jéhannin-ligier, E. Dantony, N. Bossard, F. Molinié, G. Defossez et al., Projection de l'incidence et de la mortalité en France métropolitaine en 2017 -Rapport technique -Ref : RAINCMETRO17, 2018.

M. E. Jones, M. J. Schoemaker, L. B. Wright, A. Ashworth, and A. J. Swerdlow, Smoking and risk of breast cancer in the Generations Study cohort, Breast Cancer Res. BCR, vol.19, 2017.

C. Kahlenborn, F. Modugno, D. M. Potter, and W. B. Severs, Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis, Mayo Clin. Proc, vol.81, issue.10, pp.1290-1302, 2006.

O. P. Kallioniemi, K. Holli, T. Visakorpi, T. Koivula, H. H. Helin et al., Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer, Int. J. Cancer, vol.49, issue.5, pp.650-655, 1991.

D. Karnofsky and J. Burchenal, Clinical evaluation of chemotherapeutic agents in cancer. In Columbia Univ press. Page 196. MacLeod CM, 1949.

K. M. Kelly, J. Dean, W. S. Comulada, and S. Lee, Breast cancer detection using automated whole breast ultrasound and mammography in radiographically dense breasts, Eur. Radiol, vol.20, issue.3, pp.734-742, 2010.

G. Kemmler, B. Holzner, M. Kopp, M. Dünser, R. Margreiter et al., Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.17, issue.9, pp.2932-2940, 1999.

H. Kennecke, R. Yerushalmi, R. Woods, M. C. Cheang, D. Voduc et al., Metastatic behavior of breast cancer subtypes, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.28, issue.20, pp.3271-3277, 2010.

C. R. Kennedy, F. Gao, and J. A. Margenthaler, Neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer, J. Surg. Res, vol.163, issue.1, pp.52-57, 2010.

T. Key, P. Appleby, I. Barnes, and G. Reeves, Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies, J. Natl. Cancer Inst, vol.94, issue.8, pp.606-616, 2002.

T. J. Key, P. N. Appleby, G. K. Reeves, A. Roddam, J. F. Dorgan et al., Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women, J. Natl. Cancer Inst, vol.95, issue.16, pp.1218-1226, 2003.

P. Khosravi-shahi, L. Cabezón-gutiérrez, and S. Custodio-cabello, Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies, Asia Pac. J. Clin. Oncol, vol.14, issue.1, pp.32-39, 2018.

F. Khosrow-khavar, K. B. Filion, S. Al-qurashi, N. Torabi, N. Bouganim et al., Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol, vol.28, issue.3, pp.487-496, 2017.

N. S. Knowlton, L. B. Craig, M. T. Zavy, and K. R. Hansen, Validation of the power model of ovarian nongrowing follicle depletion associated with aging in women, Fertil. Steril, vol.101, issue.3, pp.851-856, 2014.

B. B. Koolen, M. T. Vrancken-peeters, T. S. Aukema, W. V. Vogel, H. S. Oldenburg et al., 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques, Breast Cancer Res. Treat, vol.131, issue.1, pp.117-126, 2012.

D. N. Krag, S. J. Anderson, T. B. Julian, A. M. Brown, S. P. Harlow et al., Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial, Lancet Oncol, vol.11, issue.10, pp.70207-70209, 2010.

B. Kreike, M. Van-kouwenhove, H. Horlings, B. Weigelt, H. Peterse et al., Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas, Breast Cancer Res. BCR, vol.9, issue.5, p.65, 2007.

N. Kroman, A. Tutt, M. Jensen, J. Wohlfahrt, H. T. Mouridsen et al., Factors influencing the effect of age on prognosis in breast cancer: population based studyCommentary: much still to learn about relations between tumour biology, prognosis, and treatment outcome in early breast cancer, BMJ, vol.320, issue.7233, pp.474-479, 2000.

N. B. Kumar, G. H. Lyman, K. Allen, C. E. Cox, and D. V. Schapira, Timing of weight gain and breast cancer risk, Cancer, vol.76, issue.2, pp.243-249, 1995.

M. Kumle, E. Weiderpass, T. Braaten, I. Persson, H. Adami et al., Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study, Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol, vol.11, issue.11, pp.1375-1381, 2002.

M. G. Kundu and S. Acharyya, Surrogacy of progression free survival for overall survival in metastatic breast cancer studies: Meta-analyses of published studies, Contemp. Clin. Trials, vol.53, pp.20-28, 2017.

G. Kvåle and I. Heuch, Menstrual factors and breast cancer risk, Cancer, vol.62, issue.8, pp.1625-1631, 1988.

F. Kwiatkowski, M. Girard, K. Hacene, and J. Berlie, Sem : un outil de gestion informatique et statistique adapté à la recherche en cancérologie, Bull. Cancer (Paris), vol.87, issue.10, pp.715-736, 2000.

L. , Prévention et dépistage du cancer du sein, 2018.

P. H. Lahmann, K. Hoffmann, N. Allen, C. H. Gils, . Van et al., Body size and breast cancer risk: Findings from the European prospective investigation into cancer and nutrition (EPIC), Int. J. Cancer, vol.111, issue.5, pp.762-771, 2004.

S. Lal, A. E. Mccart-reed, X. M. De-luca, and P. T. Simpson, Molecular signatures in breast cancer, Methods San Diego Calif, vol.131, pp.135-146, 2017.

M. Lambertini, M. Ceppi, F. Poggio, F. A. Peccatori, H. A. Azim et al., Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol, vol.26, issue.12, pp.2408-2419, 2015.

A. Lasserre and A. Fournier, , 2016.

, Gynecol. Obstet. Fertil, vol.44, issue.7-8, pp.424-427

B. Lauby-secretan, C. Scoccianti, D. Loomis, L. Benbrahim-tallaa, V. Bouvard et al., and International Agency for Research on Cancer Handbook Working Group, N. Engl. J. Med, vol.372, issue.24, pp.2353-2358, 2015.

D. Laudisio, G. Muscogiuri, L. Barrea, S. Savastano, and A. Colao, Obesity and breast cancer in premenopausal women: Current evidence and future perspectives, Eur. J. Obstet. Gynecol. Reprod. Biol, 2018.

L. Doussal, V. Tubiana-hulin, M. Friedman, S. Hacene, K. Spyratos et al., Prognostic value of histologic grade nuclear components of Scarff-BloomRichardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas, Cancer, vol.64, issue.9, pp.1914-1921, 1989.

S. J. Lee, L. R. Schover, A. H. Partridge, P. Patrizio, W. H. Wallace et al., American Society of Clinical Oncology recommendations on fertility preservation in cancer patients, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.24, issue.18, pp.2917-2931, 2006.

S. Lefort, A. Thuleau, Y. Kieffer, P. Sirven, I. Bieche et al., CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients, Oncogene, vol.36, issue.9, pp.1211-1222, 2017.

B. D. Lehmann, J. A. Bauer, X. Chen, M. E. Sanders, A. B. Chakravarthy et al., Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, J. Clin. Invest, vol.121, issue.7, pp.2750-2767, 2011.

N. K. Leidy, D. A. Revicki, and B. Genesté, Recommendations for evaluating the validity of quality of life claims for labeling and promotion, Value Health J. Int. Soc. Pharmacoeconomics Outcomes Res, vol.2, issue.2, pp.113-127, 1999.

D. Leithner, G. Wengert, T. Helbich, E. Morris, and K. Pinker, MRI in the Assessment of BI-RADS® 4 lesions, Top. Magn. Reson. Imaging TMRI, vol.26, issue.5, pp.191-199, 2017.

B. A. Leone, C. T. Vallejo, A. O. Romero, M. R. Machiavelli, J. E. Pérez et al., Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis, Breast Cancer Res. Treat, vol.161, issue.3, pp.537-548, 2017.

A. Leplège, Le questionnaire MOS SF-36: manuel de l'utilisateur et guide d'interprétation des scores, Editions ESTEM, 2001.

A. Leplège and J. Coste, Mesure de la santé perceptuelle et de la qualité de vie: méthodes et applications. Editions Estem, 2002.

A. Leplège, E. Ecosse, A. Verdier, and T. V. Perneger, The French SF-36 Health Survey: Translation, Cultural Adaptation and Preliminary Psychometric Evaluation, J. Clin. Epidemiol, vol.51, issue.11, pp.93-99, 1998.

C. I. Li, K. E. Malone, P. L. Porter, N. S. Weiss, M. C. Tang et al., Relationship between long durations and different regimens of hormone therapy and risk of breast cancer, JAMA, vol.289, issue.24, pp.3254-3263, 2003.

J. Li, S. Chen, C. Chen, G. Di, G. Liu et al., Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy, Oncotarget, vol.8, issue.11, pp.18399-18408, 2017.

L. Li and Z. Pan, Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A MetaAnalysis of 37 Trials, Clin. Breast Cancer, vol.18, issue.1, pp.63-70, 2018.

X. Li, J. Yang, L. Peng, A. A. Sahin, L. Huo et al., Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer, Breast Cancer Res. Treat, vol.161, issue.2, pp.279-287, 2017.

F. Liebens, B. Carly, A. Pastijn, M. Fastrez, and J. Vandromme, Desire for a Child and Breast Cancer, Acta Chir. Belg, vol.108, issue.1, pp.83-87, 2008.

C. Liedtke, C. Mazouni, K. R. Hess, F. André, A. Tordai et al., Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.26, issue.8, pp.1275-1281, 2008.

G. S. Liem, F. K. Mo, E. Pang, J. J. Suen, N. L. Tang et al., ChemotherapyRelated Amenorrhea and Menopause in Young Chinese Breast Cancer Patients: Analysis on Incidence, Risk Factors and Serum Hormone Profiles, PloS One, vol.10, issue.10, p.140842, 2015.

N. U. Lin, A. Vanderplas, M. E. Hughes, R. L. Theriault, S. B. Edge et al., Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network, Cancer, vol.118, issue.22, pp.5463-5472, 2012.

C. A. Livasy, G. Karaca, R. Nanda, M. S. Tretiakova, O. I. Olopade et al., Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma, Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc, vol.19, issue.2, pp.264-271, 2006.

S. J. London, G. A. Colditz, M. J. Stampfer, W. C. Willett, B. A. Rosner et al., Prospective Study of Smoking and the Risk of Breast Cancer, JNCI J. Natl. Cancer Inst, vol.81, issue.21, pp.1625-1631, 1989.

A. W. Loren, P. B. Mangu, L. N. Beck, L. Brennan, A. J. Magdalinski et al., of Clinical Oncology clinical practice guideline update, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.31, pp.2500-2510, 2013.

J. Luo, K. L. Margolis, J. Wactawski-wende, K. Horn, C. Messina et al., Association of active and passive smoking with risk of breast cancer among postmenopausal women: a prospective cohort study, The BMJ, vol.342, 2011.

E. Luporsi, F. André, F. Spyratos, P. Martin, J. Jacquemier et al., Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review, Breast Cancer Res. Treat, vol.132, issue.3, pp.895-915, 2012.

B. Macmahon, P. Cole, T. M. Lin, C. R. Lowe, A. P. Mirra et al., Age at first birth and breast cancer risk, Bull. World Health Organ, vol.43, issue.2, pp.209-221, 1970.

C. Magnusson, J. Baron, I. Persson, A. Wolk, R. Bergström et al., Body size in different periods of life and breast cancer risk in postmenopausal women, Int. J. Cancer, vol.76, issue.1, pp.29-34, 1998.

J. E. Manson, A. K. Aragaki, J. E. Rossouw, G. L. Anderson, R. L. Prentice et al., Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials, JAMA, vol.318, issue.10, pp.927-938, 2017.

P. A. Marchbanks, J. A. Mcdonald, H. G. Wilson, S. G. Folger, M. G. Mandel et al., Oral contraceptives and the risk of breast cancer, N. Engl. J. Med, vol.346, issue.26, pp.2025-2032, 2002.

N. Mcandrew and A. Demichele, Neoadjuvant Chemotherapy Considerations in Triple-Negative Breast Cancer, J. Target. Ther. Cancer, vol.7, issue.1, pp.52-69, 2018.

S. M. Mckinlay, D. J. Brambilla, and J. G. Posner, The normal menopause transition, Am. J. Hum. Biol, vol.4, issue.1, pp.37-46, 1992.

D. Meirow, Reproduction post-chemotherapy in young cancer patients, Mol. Cell. Endocrinol, vol.169, issue.1-2, pp.123-131, 2000.

M. Mercier and S. Schraub, Quality of life : what are the assessment instruments, 2005.

M. Miaja, A. Platas, and B. A. Martinez-cannon, Psychological Impact of Alterations in Sexuality, Fertility, and Body Image in Young Breast Cancer Patients and Their Partners, Rev. Investig. Clin. Organo Hosp. Enfermedades Nutr, vol.69, issue.4, pp.204-209, 2017.

Y. Miki, J. Swensen, D. Shattuck-eidens, P. A. Futreal, K. Harshman et al., A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1, Science, vol.266, issue.5182, pp.66-71, 1994.

, Breast cancer and hormone-replacement therapy in the Million Women Study, The Lancet, vol.362, issue.9382, pp.419-427, 2003.

. Mills, Performing a clinical breast exam : Nursing2013, 2013.

M. N. Mills, G. Q. Yang, D. E. Oliver, C. L. Liveringhouse, K. A. Ahmed et al., Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis, Eur. J. Cancer, vol.98, pp.48-58, 2018.

G. Von-minckwitz, M. Untch, J. Blohmer, S. D. Costa, H. Eidtmann et al., Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.30, issue.15, pp.1796-1804, 2012.

L. S. Mørch, C. W. Skovlund, P. C. Hannaford, L. Iversen, S. Fielding et al., Contemporary Hormonal Contraception and the Risk of Breast Cancer, N. Engl. J. Med, vol.377, issue.23, pp.2228-2239, 2017.

L. M. Morimoto, E. White, Z. Chen, R. T. Chlebowski, J. Hays et al., Obesity, Body Size, and Risk of Postmenopausal Breast Cancer: The Women's Health Initiative (United States), Cancer Causes Control, vol.13, issue.8, pp.741-751, 2002.

G. J. Morris, S. Naidu, A. K. Topham, F. Guiles, Y. Xu et al., Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database, Cancer, vol.110, issue.4, pp.876-884, 2007.

J. M. Nabholtz, C. Abrial, M. A. Mouret-reynier, M. M. Dauplat, B. Weber et al., Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol, vol.25, issue.8, pp.1570-1577, 2014.

J. M. Nabholtz, N. Chalabi, N. Radosevic-robin, M. M. Dauplat, M. A. Mouret-reynier et al., Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer, Int. J. Cancer, vol.138, issue.9, pp.2274-2280, 2016.

T. O. Nielsen, F. D. Hsu, K. Jensen, M. Cheang, G. Karaca et al., Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma, Clin. Cancer Res, vol.10, issue.16, pp.5367-5374, 2004.

A. Nkondjock and P. Ghadirian, Facteurs de risque du cancer du sein. médecine/sciences, vol.21, pp.175-180, 2005.

I. Nöbauer-huhmann, A. Ba-ssalamah, V. Mlynarik, M. Barth, A. Schöggl et al., Magnetic resonance imaging contrast enhancement of brain tumors at 3 tesla versus 1.5 tesla, Invest. Radiol, vol.37, issue.3, pp.114-119, 2002.

J. M. Noh, D. H. Choi, S. J. Huh, W. Park, J. H. Yang et al., Patterns of recurrence after breast-conserving treatment for early stage breast cancer by molecular subtype, J. Breast Cancer, vol.14, issue.1, pp.46-51, 2011.

R. Odermatt, A. Wolfer, and K. Zaman, Endocrine therapy in breast cancer: efficacy and adverse events, Rev. Med. Suisse, vol.9, issue.387, pp.1090-1094, 2013.

. Oms, OMS | Constitution de l'OMS: ses principes, 1948.

E. A. O'reilly, L. Gubbins, S. Sharma, R. Tully, M. H. Guang et al., The fate of chemoresistance in triple negative breast cancer (TNBC), BBA Clin, vol.3, pp.257-275, 2015.

M. E. Ossewaarde, M. L. Bots, A. L. Verbeek, P. H. Peeters, Y. Van-der-graaf et al., Age at menopause, cause-specific mortality and total life expectancy, Epidemiol. Camb. Mass, vol.16, issue.4, pp.556-562, 2005.

V. Pala, V. Krogh, F. Berrino, S. Sieri, S. Grioni et al., Meat, eggs, dairy products, and risk of breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, Am. J. Clin. Nutr, vol.90, issue.3, pp.602-612, 2009.

D. M. Parkin, International variation, Oncogene, vol.23, issue.38, pp.6329-6340, 2004.

J. Passildas, O. Collard, A. Savoye, J. Dohou, A. Ginzac et al., Impact of Chemotherapy-induced Menopause in Women of Childbearing Age With Non-metastatic Breast Cancer -Preliminary Results From the MENOCOR Study, Clin. Breast Cancer, vol.19, issue.1, pp.74-84, 2019.
URL : https://hal.archives-ouvertes.fr/hal-01904507

D. A. Patel, J. Xi, J. Luo, B. Hassan, S. Thomas et al., Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triplenegative breast cancer, Breast Cancer Res. Treat, 2019.

T. Patel and P. Rajiah, Lung Metastases Imaging: Practice Essentials, Radiography, Computed Tomography, 2018.

F. Penault-llorca, F. André, C. Sagan, M. Lacroix-triki, Y. Denoux et al., Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.27, issue.17, pp.2809-2815, 2009.

F. Penault-llorca, A. Cayre, F. Bouchet-mishellany, S. Amat, V. Feillel et al., Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome, Int. J. Oncol, vol.22, issue.6, pp.1319-1325, 2003.

C. M. Perou, T. Sørlie, M. B. Eisen, M. Van-de-rijn, S. S. Jeffrey et al., Molecular portraits of human breast tumours, Nature, vol.406, issue.6797, pp.747-752, 2000.

M. J. Piccart-gebhart, M. Procter, B. Leyland-jones, A. Goldhirsch, M. Untch et al., Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer, N. Engl. J. Med, vol.353, issue.16, pp.1659-1672, 2005.

S. E. Pinder, I. O. Ellis, M. Galea, S. O'rouke, R. W. Blamey et al., Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up, Histopathology, vol.24, issue.1, pp.41-47, 1994.

B. Pistilli, C. Mazouni, A. Zingarello, M. Faron, M. Saghatchian et al., Individualized Prediction of Menses Recovery After Chemotherapy for Early-stage Breast Cancer: A Nomogram Developed From UNICANCER PACS04 and PACS05 Trials, Clin. Breast Cancer, vol.19, issue.1, 2019.

X. Pivot, G. Romieu, M. Debled, J. Pierga, P. Kerbrat et al., and PHARE trial investigators. 2013. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial, Lancet Oncol, vol.14, issue.8, pp.70225-70225

, Plan Cancer 2014-2019 -Ref : PLANKPNRT14, 2014.

M. L. Plasilova, B. Hayse, B. K. Killelea, N. R. Horowitz, A. B. Chagpar et al., Features of triple-negative breast cancer, Medicine (Baltimore), issue.35, p.95, 2016.

K. Pogoda, A. Niwi?ska, M. Murawska, and T. Pie?kowski, Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients, Med. Oncol. Northwood Lond. Engl, vol.30, issue.1, p.388, 2013.

A. Prat, B. Adamo, M. C. Cheang, C. K. Anders, L. A. Carey et al., Molecular characterization of basal-like and non-basal-like triple-negative breast cancer, The Oncologist, vol.18, issue.2, pp.123-133, 2013.

M. F. Press, L. Bernstein, P. A. Thomas, L. F. Meisner, J. Y. Zhou et al., HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.15, issue.8, pp.2894-2904, 1997.

, Quelques chiffres -Cancer du sein | Institut National Du Cancer, 2018.

N. Radosevic-robin, C. Abrial, M. Dauplat, M. Roche, A. Cayre et al., Abstract 1819: Heterogeneity of triplenegative breast cancer response to neoadjuvant treatment: tumor EGFR, HER3 and MET expressions can provide clues for therapy tailoring, Cancer Res, vol.74, pp.1819-1819, 2014.

N. Radosevic-robin, E. Cocco, M. Privat, C. Abrial, F. Penault-llorca et al., Abstract P2-09-29: Potential recurrence markers of locally advanced triple negative breast cancer treated by combined neoadjuvant EGFR targeting and chemotherapy, revealed by genomic analyses and assessment of tumor-infiltrating lymphocytes, Cancer Res, vol.78, pp.2-09, 2018.

E. A. Rakha, C. , and S. , Metastatic triple-negative breast cancer, Clin. Oncol. R. Coll. Radiol. G. B, vol.23, issue.9, pp.587-600, 2011.

M. M. Regan, P. Neven, A. Giobbie-hurder, A. Goldhirsch, B. Ejlertsen et al., BIG 1-98 Collaborative Group, and International Breast Cancer Study Group (IBCSG). 2011. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up, Lancet Oncol, vol.12, issue.12, pp.1101-1108

A. Reh, O. Oktem, and K. Oktay, Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers, Fertil. Steril, vol.90, issue.5, pp.1635-1639, 2008.

W. J. Rejeski and S. L. Mihalko, Physical Activity and Quality of Life in Older Adults, J. Gerontol. Ser. A, vol.56, issue.suppl_2, pp.23-35, 2001.

S. A. Robert, I. Strombom, A. Trentham-dietz, J. M. Hampton, J. A. Mcelroy et al., Socioeconomic risk factors for breast cancer: distinguishing individual-and community-level effects, Epidemiol. Camb. Mass, vol.15, issue.4, pp.442-450, 2004.

Q. Romero, P. Bendahl, M. Fernö, D. Grabau, and S. Borgquist, A novel model for Ki67 assessment in breast cancer, Diagn. Pathol, vol.9, p.118, 2014.

L. Rosenberg, Y. Zhang, P. F. Coogan, B. L. Strom, and J. R. Palmer, A Case-Control Study of Oral Contraceptive Use and Incident Breast Cancer, Am. J. Epidemiol, vol.169, issue.4, pp.473-479, 2009.

L. Rosero-bixby, M. W. Oberle, and N. C. Lee, Reproductive history and breast cancer in a population of high fertility, Costa Rica, 1984-85, Int. J. Cancer, vol.40, issue.6, pp.747-754, 1987.

J. S. Ross and J. A. Fletcher, The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy, Stem Cells Dayt. Ohio, vol.16, issue.6, pp.413-428, 1998.

J. E. Rossouw, G. L. Anderson, R. L. Prentice, A. Z. Lacroix, C. Kooperberg et al., and Writing Group for the Women's Health Initiative Investigators. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial, JAMA, vol.288, issue.3, pp.321-333

O. M. Rueda, S. Sammut, J. A. Seoane, S. Chin, J. L. Caswell-jin et al., Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups, Nature, vol.567, issue.7748, p.399, 2019.

M. R. Safarinejad, N. Shafiei, and S. Safarinejad, Quality of life and sexual functioning in young women with early-stage breast cancer 1 year after lumpectomy, Psychooncology, vol.22, issue.6, pp.1242-1248, 2013.

M. Saghatchian, C. Bouleuc, C. Naudet, S. Arnaud, P. Papazian et al., , 2018.

, Bull. Cancer (Paris), pp.671-678

A. Santonja, A. Sánchez-muñoz, A. Lluch, M. R. Chica-parrado, J. Albanell et al., Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy, Oncotarget, vol.9, issue.41, pp.26406-26416, 2018.

N. Santoro, S. L. Crawford, S. R. El-khoudary, A. A. Allshouse, S. Burnett-bowie et al., Menstrual Cycle Hormone Changes in Women Traversing Menopause: Study of Women's Health Across the Nation, J. Clin. Endocrinol. Metab, vol.102, issue.7, pp.2218-2229, 2017.

N. Santoro, C. N. Epperson, and S. B. Mathews, Menopausal Symptoms and Their Management, Endocrinol. Metab. Clin. North Am, vol.44, issue.3, pp.497-515, 2015.

D. P. Saraiva, G. Cabral, M. Jacinto, A. Braga, and S. , How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment, ESMO Open, vol.2, issue.4, p.208, 2017.

F. Sardanelli, C. Boetes, B. Borisch, T. Decker, M. Federico et al., Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group, Eur. J. Cancer Oxf. Engl, vol.46, issue.8, pp.1296-1316, 1990.

D. M. Sataloff, B. A. Mason, A. J. Prestipino, U. L. Seinige, C. P. Lieber et al., Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome, J. Am. Coll. Surg, vol.180, issue.3, pp.297-306, 1995.

K. Sato, M. Shimizu, and M. Miyashita, Which quality of life instruments are preferred by cancer patients in Japan? Comparison of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 and the Functional Assessment of Cancer Therapy-General. Support. Care Cancer Off, J. Multinatl. Assoc. Support. Care Cancer, vol.22, issue.12, pp.3135-3141, 2014.

K. Schneider, K. Zelley, K. E. Nichols, and J. Garber, Li-Fraumeni Syndrome, GeneReviews®, 1993.
URL : https://hal.archives-ouvertes.fr/hal-01262929

S. F. Schoppmann, G. Bayer, K. Aumayr, S. Taucher, S. Geleff et al., Prognostic Value of Lymphangiogenesis and Lymphovascular Invasion in Invasive Breast Cancer, Ann. Surg, vol.240, issue.2, pp.306-312, 2004.

Y. T. Van-der-schouw, Y. Van-der-graaf, E. W. Steyerberg, M. J. Eijkemans, and J. D. Banga, Age at menopause as a risk factor for cardiovascular mortality, The Lancet, vol.347, issue.9003, pp.90075-90081, 1996.

E. Senkus, S. Kyriakides, S. Ohno, F. Penault-llorca, P. Poortmans et al., Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol, vol.26, issue.5, 2015.

R. Sever and B. , Signal Transduction in Cancer, p.29, 2015.

M. Sezik, O. Ozkaya, F. Demir, H. T. Sezik, and H. Kaya, Total salpingectomy during abdominal hysterectomy: Effects on ovarian reserve and ovarian stromal blood flow, J. Obstet. Gynaecol. Res, vol.33, issue.6, pp.863-869, 2007.

Z. Shao, S. Chaudhri, M. Guo, L. Zhang, R. et al., Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study, Oncol. Res, vol.23, issue.6, pp.291-302, 2016.

S. Shapiro, Evidence on screening for breast cancer from a randomized trial, Cancer, vol.39, issue.6, pp.2772-2782, 1977.

S. Shapiro, W. Venet, P. Strax, L. Venet, and R. Roeser, Selection, follow-up, and analysis in the Health Insurance Plan Study: a randomized trial with breast cancer screening, Natl. Cancer Inst. Monogr, vol.67, pp.65-74, 1985.

B. Shim, M. Jin, J. Hye-moon, I. A. Park, S. Ryu et al., High Cytoplasmic CXCR4 Expression Predicts Prolonged Survival in Triple-Negative Breast Cancer Patients, J. Pathol. Transl. Med, vol.52, 2018.

D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich et al., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, vol.235, issue.4785, pp.177-182, 1987.

D. J. Slamon, B. Leyland-jones, S. Shak, H. Fuchs, V. Paton et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N. Engl. J. Med, vol.344, issue.11, pp.783-792, 2001.

T. J. Smith, S. Temin, E. R. Alesi, A. P. Abernethy, T. A. Balboni et al., American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.30, issue.8, pp.880-887, 2012.

Y. J. Song, S. H. Shin, J. S. Cho, M. H. Park, J. H. Yoon et al., The Role of Lymphovascular Invasion as a Prognostic Factor in Patients with Lymph NodePositive Operable Invasive Breast Cancer, J. Breast Cancer, vol.14, issue.3, pp.198-203, 2011.

T. Sørlie, C. M. Perou, R. Tibshirani, T. Aas, S. Geisler et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc. Natl. Acad. Sci. U. S. A, vol.98, pp.10869-10874, 2001.

C. Sotiriou, S. Neo, L. M. Mcshane, E. L. Korn, P. M. Long et al., Breast cancer classification and prognosis based on gene expression profiles from a population-based study, Proc. Natl. Acad. Sci. U. S. A, vol.100, issue.18, pp.10393-10398, 2003.

M. R. Soules, S. Sherman, E. Parrott, R. Rebar, N. Santoro et al., Executive summary: stages of reproductive aging workshop (STRAW), Fertil. Steril, vol.76, issue.5, pp.874-878, 2001.

M. A. Sprangers, M. Groenvold, J. I. Arraras, J. Franklin, A. Te-velde et al., The European Organization for Research and Treatment of Cancer breast cancerspecific quality-of-life questionnaire module: first results from a three-country field study, J. Clin. Oncol, vol.14, issue.10, pp.2756-2768, 1996.

L. Steward, L. Conant, F. Gao, and J. A. Margenthaler, Predictive factors and patterns of recurrence in patients with triple negative breast cancer, Ann. Surg. Oncol, vol.21, issue.7, pp.2165-2171, 2014.

B. Stoll, Teenage obesity in relation to breast cancer risk, Int. J. Obes, vol.22, issue.11, 1998.

D. G. Stover, C. F. Bell, and S. M. Tolaney, Neoadjuvant and Adjuvant Chemotherapy Considerations for Triple-Negative Breast Cancer, Am. J. Hematol. Oncol, vol.12, issue.3, 2016.

H. I. Su and E. W. Freeman, Hormone changes associated with the menopausal transition, Minerva Ginecol, vol.61, issue.6, pp.483-489, 2009.

Y. Sun, Z. Zhao, Z. Yang, F. Xu, H. Lu et al., Risk Factors and Preventions of Breast Cancer, Int. J. Biol. Sci, vol.13, pp.1387-1397, 2017.

A. J. Swerdlow and M. E. Jones, Tamoxifen Treatment for Breast Cancer and Risk of Endometrial Cancer: A Case-Control Study, JNCI J. Natl. Cancer Inst, vol.97, issue.5, pp.375-384, 2005.

W. F. Symmans, F. Peintinger, C. Hatzis, R. Rajan, H. Kuerer et al., Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.25, issue.28, pp.4414-4422, 2007.

M. Tan, J. L. Mester, J. Ngeow, L. A. Rybicki, M. S. Orloff et al., Lifetime Cancer Risks in Individuals with Germline PTEN Mutations, Clin. Cancer Res, vol.18, issue.2, pp.400-407, 2012.

M. Tao, H. Shao, C. Li, and Y. Teng, Correlation between the modified Kupperman Index and the Menopause Rating Scale in Chinese women, Patient Prefer. Adherence, vol.7, pp.223-229, 2013.

, Indicateurs d'évaluation / Evaluation du programme de dépistage du cancer du sein / Evaluation des programmes de dépistage des cancers / Cancers / Maladies chroniques et traumatismes / Dossiers thématiques / Accueil, 2018.

B. Tehard, R. Kaaks, and F. Clavel-chapelon, Body silhouette, menstrual function at adolescence and breast cancer risk in the E3N cohort study, Br. J. Cancer, vol.92, issue.11, pp.2042-2048, 2005.
URL : https://hal.archives-ouvertes.fr/inserm-00127340

P. Terry, M. Jain, A. B. Miller, G. R. Howe, and T. E. Rohan, Dietary carotenoids and risk of breast cancer, Am. J. Clin. Nutr, vol.76, issue.4, pp.883-888, 2002.

A. A. Thike, J. Iqbal, P. Y. Cheok, A. P. Chong, G. M. Tse et al., Triple Negative Breast Cancer: Outcome Correlation With Immunohistochemical Detection of Basal Markers, Am. J. Surg. Pathol, vol.34, issue.7, pp.956-964, 2010.

F. Torino, A. Barnabei, L. De-vecchis, V. Sini, F. Schittulli et al., Chemotherapy-induced ovarian toxicity in patients affected by endocrineresponsive early breast cancer, Crit. Rev. Oncol. Hematol, vol.89, issue.1, pp.27-42, 2014.

A. E. Treloar, Menstrual cyclicity and the pre-menopause, Maturitas, vol.3, issue.3, pp.249-264, 1981.

J. Tsai, D. Bertoni, T. Hernandez-boussard, M. L. Telli, and I. L. Wapnir, Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer, Ann. Surg. Oncol, vol.23, issue.10, pp.3310-3316, 2016.

. Uicc, TNM Classification of Malignant Tumours -Google Livres, 2016.

P. Valagussa, D. De-candis, G. Antonelli, and G. Bonadonna, VIII. Women's health perception and breast cancer: issues of fertility, hormone substitution, and cancer prevention. Recent Results Cancer Res, Fortschritte Krebsforsch. Progres Dans Rech. Sur Cancer, vol.140, pp.277-283, 1996.

L. Vanlemmens, E. Fournier, D. Boinon, J. Machavoine, C. et al., Qualité de vie des femmes jeunes ayant un cancer du sein localisé et de leur partenaire : nécessité de développement de questionnaires spécifiques pour la patiente et le partenaire, Bull. Cancer (Paris), vol.99, issue.6, pp.685-691, 2012.

E. R. Te-velde and P. L. Pearson, The variability of female reproductive ageing, Hum. Reprod. Update, vol.8, issue.2, pp.141-154, 2002.

M. Vessey and R. Painter, Oral contraceptive use and cancer. Findings in a large cohort study, Br. J. Cancer, vol.95, issue.3, pp.385-389, 1968.

R. Vieira, J. S. Tobar, R. Dardes, and L. C. Thuler, Alcohol Consumption as a Risk Factor for Breast Cancer Development: A Case-Control Study in Brazil. Asian Pac, J. Cancer Prev. APJCP, vol.19, issue.3, pp.703-707, 2018.

T. J. Villiers, . De, M. L. Gass, C. J. Haines, J. E. Hall et al., Global Consensus Statement on menopausal hormone therapy, Maturitas, vol.74, issue.4, pp.391-392, 2013.

D. J. Van-der-voort, P. H. Van-der-weijer, and R. Barentsen, Early menopause: increased fracture risk at older age, Osteoporos. Int, vol.14, issue.6, pp.525-530, 2003.

H. Vorherr, The Breast: Morphology, Physiology, and Lactation, 2012.

W. H. Wallace and T. W. Kelsey, Human Ovarian Reserve from Conception to the Menopause, PLOS ONE, vol.5, issue.1, p.8772, 2010.

J. Wan, Y. Gai, G. Li, Z. Tao, and Z. Zhang, Incidence of chemotherapy-and chemoradiotherapy-induced amenorrhea in premenopausal women with stage II/III colorectal cancer, Clin. Colorectal Cancer, vol.14, issue.1, pp.31-34, 2015.

X. Wang, Y. Jiang, J. Li, C. Song, and Z. Shao, Effect of nodal status on clinical outcomes of triple-negative breast cancer: a population-based study using the SEER 18 database, Oncotarget, vol.7, issue.29, pp.46636-46645, 2016.

C. A. Van-wayenburg, Y. T. Van-der-schouw, P. A. Van-noord, and P. H. Peeters, Age at menopause, body mass index, and the risk of colorectal cancer mortality in the Dutch Diagnostisch Onderzoek Mammacarcinoom (DOM) cohort, Epidemiol. Camb. Mass, vol.11, issue.3, pp.304-308, 2000.

. Who, Study protocol for the World Health Organization project to develop a Quality of Life assessment instrument (WHOQOL). Qual, Life Res. Int. J. Qual. Life Asp. Treat. Care Rehabil, vol.2, issue.2, pp.153-159, 1993.

. Who, Research on the menopause in the 1990's, 1996.

I. Wiklund, Methods of assessing the impact of climacteric complaints on quality of life, Maturitas, vol.29, issue.1, pp.41-50, 1998.

M. Wiseman, The Second World Cancer Research Fund/American Institute for Cancer Research Expert Report. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective, Proc. Nutr. Soc, vol.67, issue.03, pp.253-256, 2008.

A. C. Wolff, M. E. Hammond, K. H. Allison, B. E. Harvey, P. B. Mangu et al., College of American Pathologists Clinical Practice Guideline Focused Update, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.36, issue.20, pp.2105-2122, 2018.

A. C. Wolff, M. E. Hammond, D. G. Hicks, M. Dowsett, L. M. Mcshane et al., American Society of Clinical Oncology, and College of American Pathologists. 2013. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.31, issue.31, pp.3997-4013

R. Wooster, G. Bignell, J. Lancaster, S. Swift, S. Seal et al., Identification of the breast cancer susceptibility gene BRCA2, Nature, vol.378, issue.6559, pp.789-792, 1995.

, Food, nutrition, physical activity, and the prevention of cancer: a global perspective, vol.1, 2007.

X. Wu, A. Baig, G. Kasymjanova, K. Kafi, C. Holcroft et al., Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype, Cureus, vol.8, issue.12, 2016.

Y. Wu, D. Zhang, and S. Kang, Physical activity and risk of breast cancer: a metaanalysis of prospective studies, Breast Cancer Res. Treat, vol.137, issue.3, pp.869-882, 2013.

M. Wunderle, G. Olmes, N. Nabieva, L. Häberle, S. M. Jud et al., Risk, Prediction and Prevention of Hereditary Breast Cancer -Large-Scale Genomic Studies in Times of Big and Smart Data, Geburtshilfe Frauenheilkd, vol.78, issue.05, pp.481-492, 2018.

L. B. Xue, Y. H. Liu, B. Zhang, Y. F. Yang, D. Yang et al., Prognostic role of high neutrophil-to-lymphocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy: Meta-analysis, Medicine (Baltimore), vol.98, issue.1, p.13842, 2019.

Y. Yarden and M. X. Sliwkowski, Untangling the ErbB signalling network, Nat. Rev. Mol. Cell Biol, vol.2, issue.2, pp.127-137, 2001.

S. Yin, R. Njai, L. Barker, P. Z. Siegel, and Y. Liao, Summarizing health-related quality of life (HRQOL): development and testing of a one-factor model, Popul. Health Metr, vol.14, 2016.

W. Yin, Y. Jiang, Z. Shen, Z. Shao, and J. Lu, Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials, PLOS ONE, vol.6, issue.6, p.21030, 2011.

L. C. Yong, C. C. Brown, A. Schatzkin, and C. Schairer, Prospective study of relative weight and risk of breast cancer: the Breast Cancer Detection Demonstration Project follow-up study, Am. J. Epidemiol, vol.143, issue.10, pp.985-995, 1979.

S. Yu, X. Wang, G. Liu, X. Zhu, C. et al., High level of CXCR4 in triplenegative breast cancer specimens associated with a poor clinical outcome, Acta Med. Okayama, vol.67, issue.6, pp.369-375, 2013.

P. Zhang, C. Li, G. Jiao, J. Zhang, H. Zhao et al., Effects of ovarian ablation or suppression in premenopausal breast cancer: A meta-analysis of randomized controlled trials, Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol, vol.43, issue.7, pp.1161-1172, 2017.

E. S. Zhou, S. J. Falk, and S. L. Bober, Managing premature menopause and sexual dysfunction, Curr. Opin. Support. Palliat. Care, vol.9, issue.3, pp.294-300, 2015.

R. G. Ziegler, R. N. Hoover, M. C. Pike, A. M. Nomura, D. W. West et al., , 1993.